Solventum Corporation
SOLV NYSEHealthcare ★★★★★Latest Earnings Above forecast↑
Date
Aug 5, 2026
ET
EPS Est.
1.90
EPS Actual
2.55
Revenue Est.
$2.15B
Revenue Actual
$2.21B
Next Earnings Report
Date
Nov 5, 2026 · Thu
Time
After-market
Fiscal Period
FY2026 Q3
EPS Est.
1.35
Revenue Est.
$1.93B
Company Overview
Solventum Corporation (ticker SOLV) is listed on NYSE with a market cap of about $15.51B. Its next earnings report (FY2026 Q3) is expected on Nov 5, 2026 (ET), After-market, with consensus EPS of 1.35. In the last 10 reported quarters, EPS beat consensus estimates 10 times.
Actual EPS TrendRecently15Term · Dec 31, 2022 → Aug 5, 2026
Dec 31, 2022Range: 1.34 ~ 2.55Aug 5, 2026
Earnings History
| Date | Fiscal Period | EPS Est. | EPS Actual | Revenue Est. | Revenue Actual |
|---|---|---|---|---|---|
| Aug 5, 2026 | -- | 1.90 | Above forecast↑2.55 | $2.15B | $2.21B |
| May 5, 2026 | -- | 1.35 | 1.48 | $1.97B | $2.01B |
| Feb 26, 2026 | -- | 1.50 | 1.57 | $1.96B | $2B |
| Nov 6, 2025 | -- | 1.43 | 1.50 | $2.06B | $2.1B |
| Aug 7, 2025 | -- | 1.45 | Above forecast↑1.69 | $2.12B | $2.16B |
| May 8, 2025 | -- | 1.21 | 1.34 | $2.02B | $2.07B |
| Feb 27, 2025 | -- | 1.31 | 1.41 | $2.05B | $2.07B |
| Nov 7, 2024 | -- | 1.39 | Above forecast↑1.64 | $2.06B | $2.08B |
| Aug 8, 2024 | -- | 1.51 | 1.56 | $2.05B | $2.08B |
| May 9, 2024 | -- | 1.75 | Above forecast↑2.08 | $1.97B | $2.02B |
| Mar 11, 2024 | -- | -- | 2.31 | -- | $2.04B |
| Sep 30, 2023 | -- | -- | 1.65 | -- | $2.05B |
| Jun 30, 2023 | -- | -- | 1.86 | -- | $2.04B |
| Mar 31, 2023 | -- | -- | 1.70 | -- | $2.04B |
| Dec 31, 2022 | -- | -- | 1.78 | -- | $2.01B |
Original Filings (SEC)
10-Q2026-08-05 ↗
8-K2026-08-05 ↗
8-K2026-08-05 ↗
8-K2026-07-20 ↗
8-K2026-06-05 ↗
8-K2026-05-27 ↗
8-K2026-05-20 ↗
10-Q2026-05-05 ↗
Links point to the company's original filings on the U.S. Securities and Exchange Commission (SEC) website.
Report dates are US trading days (Eastern Time); EPS and revenue estimates are market consensus, in USD. This page is for reference only and does not constitute investment advice.
